Evogene Ltd EVGN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Lavie Bio Announces a Distribution Agreement with WinField United Canada for its Bio-Inoculant Seed Treatment Yalos™
-
Lavie Bio Announces Expansion of its Bio-Inoculant Product for Spring Wheat, Yalos™, to Durum and Barley
-
Evogene Reports Third Quarter 2023 Financial Results
-
Lavie Bio Reports Advancement in Bio-Fungicide Program Against Downy Mildew with 2023 Field Trial Results
-
Evogene Schedules Third Quarter 2023 Financial Results Release & Conference Call for November 15, 2023
-
Colors Farm, Evogene and Ben-Gurion University Collaborate to Establish Crustacean Gene Editing Technology
-
Evogene Provides Operational Update Amidst Current Security Situation in Israel
-
Casterra Delivers First Shipment of Castor Seeds to Africa
Trading Information
- Previous Close Price
- $0.84
- Day Range
- $0.82–0.86
- 52-Week Range
- $0.45–1.44
- Bid/Ask
- $0.81 / $0.86
- Market Cap
- $42.47 Mil
- Volume/Avg
- 323,587 / 124,657
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 6.36
- Dividend Yield
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 137
- Website
- https://www.evogene.com
Valuation
Metric
|
EVGN
|
---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.29 |
Price/Sales | 6.36 |
Price/Cash Flow | — |
Financial Strength
Metric
|
EVGN
|
---|---|
Quick Ratio | 6.24 |
Current Ratio | 6.25 |
Interest Coverage | −31.26 |
Profitability
Metric
|
EVGN
|
---|---|
Return on Assets (Normalized) | −37.81% |
Return on Equity (Normalized) | −92.05% |
Return on Invested Capital (Normalized) | −46.24% |
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Hnhy | $445.3 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Mjgvt | $91.1 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Qsytkp | $91.1 Bil | |
SGEN
| Seagen Inc Ordinary Shares | Gqrxt | $40.7 Bil | |
MRNA
| Moderna Inc | Brys | $30.7 Bil | |
ARGX
| argenx SE ADR | Jnlnm | $27.7 Bil | |
BNTX
| BioNTech SE ADR | Ktft | $24.1 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Nntldy | $22.0 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Xzhjst | $17.7 Bil | |
INCY
| Incyte Corp | Jztpzf | $12.4 Bil |